{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:49:01Z","timestamp":1767134941721,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd010288.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T00:00:00Z","timestamp":1632268800000}}],"reference-count":47,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010288.pub5","type":"journal-article","created":{"date-parts":[[2021,9,22]],"date-time":"2021-09-22T21:05:50Z","timestamp":1632344750000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis"],"prefix":"10.1002","volume":"2021","author":[{"given":"Kana R","family":"Jat","sequence":"additional","affiliation":[{"name":"Department of Pediatrics; All India Institute of Medical Sciences (AIIMS); New Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dinesh K","family":"Walia","sequence":"additional","affiliation":[{"name":"Department of Community Medicine; Govt. Medical College and Hospital (GMCH); Chandigarh India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anju","family":"Khairwa","sequence":"additional","affiliation":[{"name":"Department of Pathology; University College of Medical Sciences (UCMS); Delhi India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,22]]},"reference":[{"key":"10.1002\/14651858.CD010288.pub5-BIB0001|cit1","unstructured":"An exploratory, randomized, double-blind, placebo controlled study to assess the efficacy of multiple doses of omalizumab (Xolair) in cystic fibrosis complicated by allergic bronchopulmonary aspergillosis - ND www.who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2007-006648-23-IT"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0002|cit2","unstructured":"An exploratory study to assess multiple doses of omalizumab in patients with cystic fibrosis complicated by acute bronchopulmonary aspergillosis (ABPA) clinicaltrials.gov\/ct2\/show\/NCT00787917"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1378\/chest.08-2586","article-title":"Allergic bronchopulmonary aspergillosis","volume":"135","author":"Agarwal","year":"2009","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD010288.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1378\/chest.109.6.1536","article-title":"Prevalence of allergic bronchopulmonary aspergillosis and atopy in adult patients with cystic fibrosis","volume":"109","author":"Becker","year":"1996","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD010288.pub5-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1398-9995.2009.02147.x","article-title":"Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis","volume":"65","author":"Brinkmann","year":"2010","journal-title":"Allergy"},{"issue":"11","key":"10.1002\/14651858.CD010288.pub5-BIB0006|cit6","first-page":"900","article-title":"Prevalence of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis in the state of Bahia, Brazil","volume":"34","author":"Costa","year":"2008","journal-title":"Jornal Brasileiro De Pneumologia: Publication Oficial Da Sociedade Brasileira De Pneumologia E Tisilogia"},{"issue":"5","key":"10.1002\/14651858.CD010288.pub5-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1172\/JCI119252","article-title":"The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics","volume":"99","author":"Corne","year":"1997","journal-title":"Journal of Clinical Investigation"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0008|cit8","unstructured":"Deeks JJ Higgins JPT Altman DG on behalf of the Cochrane Statistical Methods Group Chapter 9: \u00a0Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"11","key":"10.1002\/14651858.CD010288.pub5-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002204.pub3","article-title":"Antifungal therapies for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Elphick","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/1060028015624204","article-title":"Omalizumab Treatment for Allergic Bronchopulmonary Aspergillosis in Cystic Fibrosis","volume":"50","author":"Emiralioglu","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1002\/14651858.CD010288.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1164\/ajrccm.155.6.9196082","article-title":"The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects","volume":"155","author":"Fahy","year":"1997","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010288.pub5-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jpeds.2008.05.005","article-title":"Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report","volume":"153","author":"Farrell","year":"2008","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1378\/chest.116.3.639","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: reported prevalence, regional distribution, and patient characteristics. Scientific Advisory Group, Investigators, and Coordinators of the Epidemiologic Study of Cystic Fibrosis","volume":"116","author":"Geller","year":"1999","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD010288.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1067\/mai.2002.130179","article-title":"Allergic bronchopulmonary aspergillosis","volume":"110","author":"Greenberger","year":"2002","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"4","key":"10.1002\/14651858.CD010288.pub5-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1002\/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.0.CO;2-6","article-title":"Differential IgE recognition of recombinant Aspergillus fumigatus allergens by cystic fibrosis patients with allergic bronchopulmonary aspergillosis or Aspergillus allergy","volume":"28","author":"Hemmann","year":"1998","journal-title":"European Journal of Immunology"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0016|cit16","unstructured":"Higgins JPT Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0017|cit17","unstructured":"Higgins JPT Altman DG Sterne JAC on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"4","key":"10.1002\/14651858.CD010288.pub5-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1365-2222.2004.1916.x","article-title":"Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma","volume":"34","author":"Holgate","year":"2004","journal-title":"Clinical and Experimental Allergy: Journal of the British Society for Allergy and Clinical Immunology"},{"issue":"12","key":"10.1002\/14651858.CD010288.pub5-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatric Pulmonology"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.2741\/994","article-title":"Lymphocytes in allergic bronchopulmonary aspergillosis","volume":"8","author":"Knutsen","year":"2003","journal-title":"Frontiers in Bioscience: A Journal and Virtual Library"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0021|cit21","unstructured":"Knutsen AP Slavin RG Allergic bronchopulmonary aspergillosis in asthma and cystic fibrosis Clinical & Developmental Immunology"},{"issue":"1","key":"10.1002\/14651858.CD010288.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jcf.2019.07.011","article-title":"Omalizumab for asthma and allergic bronchopulmonary aspergillosis in adults with cystic fibrosis","volume":"19","author":"Koutsokera","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"bcr07.2008.0379","DOI":"10.1136\/bcr.07.2008.0379","article-title":"Omalizumab for exacerbations of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis","volume":"pii","author":"Lebecque","year":"2009","journal-title":"BMJ Case Reports"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1034\/j.1399-3003.2000.016003464.x","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis","volume":"16","author":"Mastella","year":"2000","journal-title":"European Respiratory Journal: Official Journal of the European Society for Clinical Respiratory Physiology"},{"issue":"4","key":"10.1002\/14651858.CD010288.pub5-BIB0025|cit25","first-page":"863","article-title":"Aspergillosis and atopy in cystic fibrosis","volume":"120","author":"Nelson","year":"1979","journal-title":"American Review of Respiratory Disease"},{"issue":"2","key":"10.1002\/14651858.CD010288.pub5-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1378\/chest.115.2.364","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis: role of atopy and response to itraconazole","volume":"115","author":"Nepomuceno","year":"1999","journal-title":"Chest"},{"issue":"6","key":"10.1002\/14651858.CD010288.pub5-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.jaci.2006.02.028","article-title":"Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma","volume":"117","author":"Noga","year":"2006","journal-title":"Journal of Allergy and Clinical Immunology"},{"issue":"1","key":"10.1002\/14651858.CD010288.pub5-BIB0028|cit28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003559.pub4","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD010288.pub5-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/ppul.23612","article-title":"Case series of omalizumab for allergic bronchopulmonary aspergillosis in cystic fibrosis patients.\u00a0","volume":"52","author":"Nov\u00e9-Josserand","year":"2017","journal-title":"Pediatr Pulmonol"},{"issue":"2","key":"10.1002\/14651858.CD010288.pub5-BIB0030|cit30","first-page":"288","article-title":"Allergic\u00a0bronchopulmonary\u00a0aspergillosis: staging as an aid to management","volume":"99","author":"Patterson","year":"1982","journal-title":"Journal of Laboratory and Clinical Medicine"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.rmed.2017.11.007","article-title":"Omalizumab treatment for allergic bronchopulmonary aspergillosis in young patients with cystic fibrosis","volume":"133","author":"Perisson","year":"2017","journal-title":"Respir Med"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0032|cit32","unstructured":"Review Manager (RevMan) The Nordic Cochrane Centre, The Cochrane Collaboration 2014"},{"issue":"4","key":"10.1002\/14651858.CD010288.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"405","DOI":"10.7326\/0003-4819-86-4-405","article-title":"Clinical and immunologic criteria for the diagnosis of allergic bronchopulmonary aspergillosis","volume":"86","author":"Rosenberg","year":"1977","journal-title":"Annals of Internal Medicine"},{"issue":"19","key":"10.1002\/14651858.CD010288.pub5-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0035|cit35","unstructured":"Chapter 14: Completing \u2018Summary of findings\u2019 tables and grading the certainty of the evidence. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0036|cit36","unstructured":"Chapter 15: Interpreting results and drawing conclusions. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019 Available from www.training.cochrane.org\/handbook"},{"issue":"1-3","key":"10.1002\/14651858.CD010288.pub5-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1159\/000237010","article-title":"Inhibition of allergic reactions with antibodies to IgE","volume":"107","author":"Shields","year":"1995","journal-title":"International Archives of Allergy and Immunology"},{"issue":"7","key":"10.1002\/14651858.CD010288.pub5-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.rmed.2004.11.018","article-title":"Prevalence of allergic bronchopulmonary aspergillosis in cystic fibrosis in an area with a high frequency of atopy","volume":"99","author":"Skov","year":"2005","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD010288.pub5-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1086\/376525","article-title":"Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference","volume":"37 Suppl 3","author":"Stevens","year":"2003","journal-title":"Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America"},{"issue":"9","key":"10.1002\/14651858.CD010288.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1023\/A:1007670717619","article-title":"Allergic bronchopulmonary aspergillosis in Italian cystic fibrosis patients: prevalence and percentage of positive tests in the employed diagnostic criteria","volume":"16","author":"Taccetti","year":"2000","journal-title":"European Journal of Epidemiology"},{"issue":"8","key":"10.1002\/14651858.CD010288.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/j.1398-9995.2005.00887.x","article-title":"Allergic bronchopulmonary aspergillosis","volume":"60","author":"Tillie-Leblond","year":"2005","journal-title":"Allergy"},{"issue":"1","key":"10.1002\/14651858.CD010288.pub5-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1089\/pai.1993.7.43","article-title":"Sensitization to aspergillus and allergic bronchopulmonary aspergillosis in a cystic fibrosis population","volume":"7","author":"Valletta","year":"1993","journal-title":"Pediatric Asthma, Allergy & Immunology"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"Ent","year":"2007","journal-title":"Thorax"},{"issue":"6","key":"10.1002\/14651858.CD010288.pub5-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1002\/ppul.20804","article-title":"Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis","volume":"43","author":"Zirbes","year":"2008","journal-title":"Pediatric Pulmonology"},{"issue":"9","key":"10.1002\/14651858.CD010288.pub5-BIB0045|cit45","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010288.pub2","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Jat","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD010288.pub5-BIB0046|cit46","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010288.pub3","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Jat","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD010288.pub5-BIB0047|cit47","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010288.pub4","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis in people with cystic fibrosis","author":"Jat","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T07:33:59Z","timestamp":1702452839000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD010288.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,9,22]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010288.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,22]]}}}